term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased.

Sub B1

2. (Amended) A method according to claim 1 wherein the LHRH antagonist is administered in a dosage to achieve the estrogen serum concentration level between about 35 pg/ml and about 80 pg/ ml.

3. (Amended) A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive.

7. (Amended) A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, a non-steroidal anti-rheumatic agent, an analgesic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.

A2

8. (Amended) A method according to claim 1 wherein the LHRH antagonist is administered starting in the early to mid follicular phase.

9. (Amended) A method according to claim 1 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and Ac-D-Nal-D-pCl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH2 LRHR antagonist.

Please add new claims 28 - 31 as follows:

--28. (NEW) A method according to claim 2, wherein said estrogen serum concentration level is between about 45-75 pg/ml.

29. (NEW) A method according to claim 28, wherein said estrogen serum concentration level is about 50 to about 75 pg/ml.

30. (NEW) A method according to claim 3, wherein said contraceptive is an oral contraceptive.

31. (NEW) A method according to claim 8, wherein the LHRH antagonist is administered on cycle day one to three.--

See the attached Appendix for the changes made to effect the above claims.